Serous carcinoma (SC) is the prototype of type-II endometrial cancer and accounts for o 10% of all endometrial carcinomas (EC). 1 It is a very aggressive tumor, unrelated to estrogen stimulation, arising occasionally in endometrial polyps or from precancerous lesions developing in atrophic endometrium that mainly occur in older women. 2 Patients with SC are at median of 5-10 years older than those with endometrioid carcinomas of the endometrium (EEC). SCs have also been reported in association with a history of breast cancer. A possible role for tamoxifen, as well as BRCA1 and BRCA2 germline mutations has been proposed, but it remains unclear whether they are key players in the link between SC and breast cancer.
SC is, by definition, regarded as high-grade tumor. The term high-risk EC has been used to include SC, clear cell carcinoma (CC), and grade 3 EEC (EEC3), because of the poor prognosis associated with these three tumor types. SC has a high tendency to develop lymph node metastasis as well as adnexal and peritoneal spread, CC is also associated with nodal metastasis, whereas EEC3 metastasizes primarily to pelvic and para-aortic lymph nodes. These three types of EC comprise~25-30% of EC, but account for 70-75% of EC deaths. SC and EEC3 have been compared using the Surveillance, Epidemiology and End Results program data from 1988 to 2001. They represented 10% and 15% of EC, respectively, but accounted for 39% and 27% of cancer deaths, respectively. SC is usually diagnosed at advanced stage; 46% of patients are at stage II-IV at presentation. [3] [4] [5] The estimated 5-year overall survival for women with SC, CC, and EEC3 is 55%, 68% and 77%, respectivly. Approximately, 60-70% of women with SC present with disease outside the uterus.
SC is defined in WHO 2014 as having complex papillary and/or glandular arrangements, with diffuse marked nuclear pleomorphism. 6 The typical microscopic features and its aggressive behavior were well described by Stanford group. 7 However, in 1974, Factor had already described the existence of papillary adenocarcinomas of the endometrium with psammoma bodies, noting their similarity to ovarian cancer. 8 In 1981, Lauchlan designated the tumors as 'tubal' or 'serous', 9 and in 1994, SC was first included in the classification of endometrial carcinomas, by WHO.
Pathologic features
The gross appearance of SC is similar to that of EEC. The uterus is usually enlarged, but occasionally small and atrophic ( Figure 1 ). Tumors are typically large, bulky, with one or several nodules protruding into the endometrial cavity, with frequent necrosis. There is often deep myometrial invasion. However, the tumor may be inconspicuous, restricted to the lining of an otherwise conventional endometrial polyp.
SC has usually, but not always, a prominent papillary pattern (Figure 2 ). In these cases, the tumor shows complex, thick, fibrotic, or edematous papillae with prominent stratification of tumor cells and cellular budding. [10] [11] [12] [13] [14] The papillae are lined by pleomorphic cells with large, eosinophilic cytoplasm, with striking cellular pseudostratification, micropapillary formation, and cell budding ( Figure 3) . Occasionally, groups of detached tumor cells may be present lying between papillae. Tumor cells are cuboidal with eosinophilic cytoplasm, but focal clearing may be noted. The nuclei are hyperchromatic or vesicular, sometimes lobulated, and display prominent macronucleoli. Over one-third of SCs contain clear cells (Figure 4a ) and cells with Figure 1 Gross appearance of uterine serous carcinoma. The tumor can fill the entire endometrial cavity or may be present as a small tumor.
hobnail configuration (Figure 4b ). In some areas, the tumor may show a solid pattern, with highly atypical cells ( Figure 5) , and in others a glandular arrangement with slit-like and irregular spaces ( Figure 6 ). The solid-and glandular-like arrangements frequently coexist with the typical papillary pattern, but may be predominant or exclusive. Mitoses are frequent, and many of them are abnormal. Although SC typically contains highly atypical cells, some tumors may show deceptively bland nuclei. Psammoma bodies may be present, but less frequently than in SC of the fallopian tube/ovary. The tumor is usually associated with deep myometrial invasion and extensive lymphatic invasion. When there is myometrial invasion, a 'gaping gland' appearance often unaccompanied by stromal reaction is frequently seen. Transition between SC and non-neoplastic endometrium is sometimes abrupt, but in many cases non-invasive tumor cells may replace endometrial surface epithelium/glands, without invading the myometrium (Figure 7) . SC typically does not arise from pre-existing endometrial hyperplasia. A precursor lesion in different stages of evolution has been described, from p53 signature to endometrial glandular dysplasia. 15, 16 These lesions usually develop in the setting of atrophic endometrium or endometrial polyps. p53 is one of the molecular abnormalities involved in the development and progression of this tumor; and tumor cells usually are strongly positive for p53 immunostaining. Like for SCs of the fallopian tube/ovary, the p53 signature is characterized by clusters of 'normal-appearing' cells with strong p53 immunostaining. Endometrial glandular dysplasia has also been suggested as a putative precursor of SC, based on histologic similarities, p53 alterations, and loss of heterozygosity patterns. Endometrial glandular dysplasia is a focal lesion, involving single glands or small groups of glands, usually measuring o 1 mm in size. Cells show hyperchromatic nuclei, but never reaching the degree of nuclear atypia seen in SC. Endometrial glandular dysplasia is more frequently seen in association with SC (53%) than with EEC (2%). Endometrial intraepithelial carcinoma (EIC) is characterized by replacement of the surface endometrial epithelium by highly atypical cells with extension to endometrial glands, with identical cytological features to invasive SC, but without stromal invasion. However, the diagnosis of EIC is discouraged, as it may be associated with high-stage disease and a fatal outcome. EIC cells may spread to the peritoneal surface via transtubal spread of tumor cells from the uterine cavity, even in absence of myometrial invasion. EIC may be found in isolation or, more commonly, adjacent to a focus of invasive SC. [17] [18] [19] [20] [21] Asuggested terminology for such tumors includes 'early/limited' SC. 14 
Prognosis
Uterine SCs are aggressive tumors. [3] [4] [5] Patients often have advanced stage tumors at initial presentation. First-line treatment is surgery. Platinum-based chemotherapy has been shown to be less effective in comparison with SC originating from fallopian tube/ovary. Surgical staging should include total hysterectomy with bilateral salpingo-oophorectomy, regional lymph node dissection, omentectomy, and peritoneal biopsies. The overall survival rate for all stages is~30-40%. [22] [23] [24] [25] [26] [27] [28] Patients with FIGO stage I disease have the highest 5-year survival rates. 29 Prognosis for SC restricted to the endometrium, or exclusively involving an endometrial polyp is much better, reaching 80% survival at 5 years in some series. Size and extent of lymphovascular invasion are also prognostically important. [30] [31] [32] The tumor may spread to cervix, fallopian tubes, ovaries, lymph nodes, peritoneum, and pleura. 33 The microscopic appearance of endometrial SC metastasizing to the peritoneum is very similar to metastatic ovarian SC. WT-1 immunostaining is helpful in this differential diagnosis. However, it is worth mentioning that WT-1 is also expressed in a reduced number of uterine SC, but staining is usually weak to moderate, in contrast to the strong and diffuse staining of ovarian SC.
Differential diagnosis
High-Grade EEC SC may exhibit a prominent solid pattern causing problems in differential diagnosis with high-grade EEC ( Table 1) . Identification of typical features of EEC or SC is helpful. It is important to pay attention to true glandular differentiation, and also squamous, mucinous, or secretory change, which favors EEC ( Figure 8 ). Coexistence with complex endometrial hyperplasia/endometrioid intraepithelial neoplasia favors an EEC, whereas the presence of EIC would support the diagnosis of SC. [34] [35] [36] [37] There are reports suggesting that high-grade EEC with mutations in POLE may be particularly prone to exhibit features mimicking SC, [38] [39] [40] including predominant solid growth, marked pleomorphism.
Low-Grade EEC
This is a very important problem 41 (Table 1) , as there is a subset of SC that shows a prominent glandular pattern, simulating a low-grade EEC at low-power magnification. [35] [36] [37] There is usually great discordance between the architectural and cytological features of the tumor. Tumor cells show high-grade atypical features with high nuclear-to-cytoplasmic ratio, prominent nuclear pleomorphism, enlarged hyperchromatic nuclei, and prominent nucleoli. Presence of obvious endometrioid differentiation, such as squamous, mucinous, or secretory change, goes against the diagnosis of SC. In contrast, SC shows marked pseudostratification, and lack of nuclear polarity (Figure 9 ), or true luminal border. It is important to pay attention to the myoinvasive front of the tumor. Patterns such as microcystic elongated fragmented favor EEC, whereas the typical "gaping gland" appearance is characteristic of SC. Another important differential diagnosis of SC is low-grade EEC with papillary (villoglandular) pattern. 42, 43 The latter shows elongated villous papillae, lacking the complex papillary pattern, as well as prominent cell stratification and papillary tufts, striking pleomorphism, and macronucleoli of SC.
Finally, SC may be confused with low-grade EEC with small nonvillous papillae ( Figure 10 ). 44 This variant accounts for 8% of EEC. The tumors contain small papillae within the endometrioid glands. The papillae are composed of buds of cells (not true papillae as in SC) with large eosinophilic cytoplasm, which typically show low-grade cytological features. Mixed endometrioid-serous carcinoma and ambiguous tumors SC usually occurs in pure form; however, occasionally, it may coexist with EEC. [45] [46] [47] It has been suggested that the serous component may arise as a result of progression of the endometrioid elements. When the second of these components is present in at least 5% of the tumor, the designation of mixed endometrial carcinoma is used, being mixed endometrioid and SC (mixed EEC-SC) the most frequent combination. The correct diagnosis of the second component is crucial to determine treatment options and outcome for these patients, 45, 46, 48 as it has been suggested that the presence of as little as 10% of a type-II component could adversely affect patient's outcome. There is some interobserver variation in histological typing in endometrial carcinoma. This is partly due to the fact that some EEC may exhibit papillary arrangements and may be erroneously mistaken as SC. On the other side, some pure SC may show a glandular growth that may be misinterpreted as EEC. Inappropriate interpretation of these unusual patterns may lead to incorrect diagnosis of mixed EEC-SC. To avoid an incorrect diagnosis of either pure EEC or SC as mixed EEC-SC, rigorous criteria should be used, and diagnosis should be confirmed with the help of immunohistochemistry or molecular tools.
Mixed EEC-SCs are ambiguous tumors. The microdissected EEC component has molecular features of EEC but also some features of SC. On the other hand, the microdissected SC component has molecular characteristics of SC (p53 mutations), but retains EEC features (K-RAS and PTEN mutations). Furthermore, there is a small group of high-grade EC tumors that are molecular and morphologically ambiguous. Classification of this small subset of tumors into SC or EEC is difficult and probably artificial. 47 
Clear cell carcinoma
As mentioned earlier, SC may exhibit cells with clear cytoplasm. These tumors should not be misinterpreted as clear cell carcinoma or mixed serous-clear cell carcinoma. Rigorous interpretation of the clear cell component is recommended when analyzing a SC. 49 Endometrial clear cell carcinoma is similar to its ovarian counterpart. Microscopically, they are characterized by a variety of patterns such as tubulocystic, papillary, glandular, and solid. Most clear cell carcinomas show mixed patterns. Tumor cells may exhibit a prominent clear appearance, due to abundant glycogen. Tumor cells may also show a hobnail configuration, which results from secretion of the cytoplasmic contents into the lumina, so the nuclei appear bulbous and protrude into the central aspects of the glands. Cystic spaces are common. Hyaline bodies are very frequent and characteristic. Clear cell adenocarcinoma usually contains small round papillae with hyalinized cores, and does not show the typical pseudostratification of SC. The nuclei are pleomorphic but uniform, with prominent nucleoli. In contrast to SC, mitotic index is low. The lumen of the glandular spaces usually contains mucin. Sheets of large cells with abundant eosinophilic (oncocytic or oxyphilic) cytoplasm, may be seen and may predominate occasionally. Clear cell carcinoma is usually (but not always) negative for estrogen receptor, and show a wild-type pattern for p53 staining. Alpha-methylacyl-CoA racemase (AMACR) and Napsin A are helpful in confirming this diagnosis. [50] [51] [52] Staining for Napsin A was seen in 87% of clear cell carcinomas, whereas only in 8% SC and no EEC in one study. 50 Moreover, AMACR immunoreactivity was seen in 75% of clear cell carcinomas, but only in 22% of EEC and 15% of SC. 51 It has been shown that hepatocyte nuclear factor 1-beta immunoreactivity lacks specificity per the diagnosis of endometrial clear cell carcinoma. 53 
Carcinosarcoma
The differential diagnosis between carcinosarcoma (malignant mixed müllerian tumor) and SC may be very difficult in small biopsies and curettages, as SC elements may predominate as the epithelial component of carcinosarcoma. The recognition of a biphasic pattern, with an obvious typical sarcomatous component, is the most important criterion for the diagnosis.
Secondary uterine involvement of adnexal serous carcinoma
SCs originating from the fallopian tube/ovary may spread to the uterus. If the SC is high grade, the differential diagnosis may be very difficult. WT-1 positivity is much more common in SC from fallopian tube/ovary in comparison with those from the endometrium; in the latter, if positive, it typically shows focal and weak staining. Moreover, drop metastases from fallopian tube/ovarian SC tend to be multifocal with small, free floating nests of tumor cells, and not associated with endometrial polyps. 54, 55 Abundant psammoma bodies slightly favor upper gynecologic tract primary origin.
Diagnosing SC in small biopsies
The diagnosis of SC may be difficult in small endometrial biopsies. It is important to look for typical features of SC, such as papillae, cell stratification and budding, slit-like spaces, and highly atypical cells. It is also important to look for lack of EEC features, such as squamous and mucinous areas, nuclear polarity, or luminal border. The presence of marked discordance between the low-grade architectural and the high-grade cytological features should alert one to the possibility of SC in a glandforming EC. Rigorous interpretation of clear cell elements and appropriate assessment of tumor stroma may be helpful in the differential diagnosis with clear cell carcinoma or carcinosarcoma. Immunohistochemistry (p53, p16, ER, IMP2, IMP3, PTEN, and Arid1A) is in general very helpful, but individual cases may show discordant features. A diagnosis of 'high-grade endometrial carcinoma, serous carcinoma component cannot be excluded' is acceptable as a managerial approach in some instances. It is important to convey that the carcinoma is high grade and that a serous component cannot be excluded, so it could be taken into account at the time of final surgery.
Molecular features of SC
cDNA array studies have demonstrated that the expression profiling of EEC is different from that of SC. In one study, 191 genes exhibited a greater than twofold differences between 10 EECs and 16 SCs. One of the genes, FOLR TFF3 was significantly upregulated in SC. 55 In another study, a different expression profile was seen between EEC and SC. Interestingly, estrogen-regulated genes were upregulated in EEC, whereas SC showed increased expression of genes involved in the regulation of the mitotic spindle checkpoint. 56 Two additional studies demonstrated differentially expression between EECs and SC. 57 The methylation profile of SC is also different from that of EEC; methylation of CDKN2B and TP73 was quite typical of SC. 58 P53 is the most frequent mutated gene (90%), probably involved in early stages of tumor development, as it is frequently abnormal in SC restricted to the endometrial surface, without myometrial invasion. P53 mutations may be demonstrated by immunohistochemistry showing the typical 'all or nothing' pattern (strong diffuse positivity or total absence of staining), which contrasts with the 'wild-type' pattern, characterized by focal, weak, and somewhat variable staining from area to area (Figure 11 ). 59 HER-2 has been shown to be amplified in SC in some series, but results have been inconsistently reproduced, whereas EGFR has been shown to be overexpressed in 36-56% of SC. PIK3CA is frequently mutated (15-41%) in these tumors. 60 The Cancer Genome Atlas Research Network (TCGA) has recently performed an integrating genomic characterization of EC. 61 Exome-sequence analysis revealed four groups of tumors. Group 1, comprised of EEC with mutations in POLE associated with good prognosis. Group 2, including EEC with microsatellite instability and group 3 tumors including EEC with low copy-number alterations, both showing similar progression-free survival rates, intermediate between groups 1 and 4. Group 4 (serous like) showed high number of gene copy-number alterations and p53 mutations, and worse prognosis, and was composed of most (but not all) SC, but also some EEC (many EEC3, but also some EEC1-2). In other words, there are tumors that are morphologically EEC but molecularly similar to SC, and also tumors that are microscopically SC, but molecularly similar to EEC. These ambiguous tumors show discordant Figure 11 p53 staining ('all or nothing') in endometrioid carcinoma grade 3 and serous carcinoma. Tumor cells may exhibit strong positivity, but also negativity for p53. microscopic/molecular features. The genes most frequently mutated in SC, according to TCGA are p53 (90.7%), PIK3CA (41.9%), FBXW/ (30.2%), and PPP2R1A (36.6%). Additional studies using exome-sequencing analysis have shown mutations in TAF-1 (30%). The TCGA prognostic classification has been recently validated in 152 endometrial carcinoma cases. 62, 63 Utility of immunohistochemical and molecular tools in distinguishing SC from EEC Histological type has consistently been proved to be an important predictor of survival, but also a determinant for the extent of the initial surgical procedure and subsequent use of adjuvant therapy. There is moderate to excellent agreement (0.62-0.87) in overall histologic typing, but also significant interobserver variability among high-grade tumors. In one study, 56 high-grade ECs were reviewed by three expert gynecological pathologists. Agreement between all three reviewers was obtained in 35 (62.5%) of cases, regarding the subtype diagnosis of the exclusive or predominant component. Major disagreement was noted in the remaining 20 cases (35.8%). The most frequent areas of disagreement were SC versus CC (seven cases) and SC versus EEC3 (six cases). Immunostaining for five biomarkers (p16, ER, PR, PTEN, and p53) improved histotype diagnosis in the most controversial cases. 41 In a different study, eight experienced gynecological pathologists reviewed online slides before and after receiving p53, p16, and ER immunostaining results. The average κ-values was 0.55 on the basis of microscopical examination, but improved to 0.68 after considering immunohistochemical results. 64 Several IHC markers have been shown to be differentially expressed in EEC, including EEC3, as opposed to SC ( Table 2) . Some of these markers were previously found to be differentially expressed between EEC and SC by cDNA analysis and also differentially abnormal by mutation analysis. Figure 12 ), although p16 expression may be quite strong and diffuse 77 ( Figure 13) .
As mentioned before, HER2 amplification and overexpression has been found more frequently in SC in some but not all series. 65 Claudin 3 and 4 are transmembrane tight junction proteins, frequently overexpressed in SC by immunohistochemistry, but subsequently confirmed by rt-PCR. 66 Nrf2 is a significant nuclear transcription factor that maintains intracellular redox homeostasis through regulating the transcription of target genes, with an antioxidant role. 67 HMGA-2 (high-mobility group AT-hook 2) is a non-histone DNA-binding factor that binds to AT-rich sequences in the minor groove of the DNA helix. 72, 73 IMP2 and 3 are oncofetal mRNAbinding proteins, members of the human IGF-II mRNA-binding protein family. Folate receptor alpha (FOLR1) is a membrane-bound receptor, involved in the transport of folate, as well as other regulatory cellular processes. 71 Several authors have attempted the use of panels of antibodies to help in diagnosis and prognosis of EC. Alkushi et al. 78 examined the expression profile of 12 markers (bcl-2, ER, p53, p21, p27, HER-2, E2F1, p63, PTEN, Gfi-1, B72.3, and CK5/6) in 200 EC (including 156 EEC and 13 SC) using a TMA. Seven of the 12 markers (p53, ER, bcl-2, HER-2, p27, E2F1, and PTEN) showed prognostic significance in univariate analysis. The cluster group designation was performed based on eight markers (p53, ER, bcl-2, HER-2, p27, E2F1, PTEN, and p21), and correlated with tumor grade, stage and cell type. Reid Nicholson examined 126 EC (including 42 EEC1-2, 40 EEC3, and 24 SC) using five immunomarkers. Substantial immunophenotypic diversity was observed among EC. 79 Only 70% of EEC 1 and 2 and 26% of EEC3 exhibited the typical phenotype of EEC (p16-, ER+, PR+, mCEA-, and vimentin+). Alkushi 80 also assessed the usefulness of a panel of six antibodies (ER, IMP3, p16, p53, PR, and PTEN), in a series of 180 EC including a subgroup of 58 If in biopsy/curettage, the diagnosis of serous carcinoma cannot be made with confidence, it is still important to convey that the carcinoma is high grade and that a serous component cannot be excluded, so it could be taken into account at the time of final surgery. Immunohistochemistry particularly p53, p16, IMP2, IMP3, and molecular studies may be helpful adjuncts but one should correlate with morphology as some degree of overlap occur.
